An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction (GUSTO-I)
Source: View publication →
The GUSTO-I trial demonstrated that an accelerated regimen of recombinant tissue plasminogen activator (rt-PA) combined with intravenous heparin significantly reduced 30-day mortality compared with streptokinase-based regimens in patients with acute myocardial infarction.
Key Findings
Study Design
Study Limitations
Clinical Significance
GUSTO-I established accelerated rt-PA as the gold standard for thrombolytic therapy in the pre-primary PCI era, highlighting the critical importance of early and sustained reperfusion (patency) for mortality reduction. It underscored the necessity of intravenous heparin as an essential adjunct to fibrin-specific thrombolytics.
Historical Context
Prior to GUSTO-I, the GISSI-2 and ISIS-3 trials failed to show a clear survival advantage of t-PA over streptokinase, leading to controversy regarding the benefit of more expensive fibrin-specific agents. GUSTO-I resolved this by demonstrating that the efficacy of t-PA was dependent on its accelerated administration schedule and the use of concomitant intravenous—rather than subcutaneous—heparin.
Guided Discussion
High-yield insights from every perspective
How does the fibrin specificity of recombinant tissue plasminogen activator (rt-PA) differentiate its clinical efficacy and side-effect profile from streptokinase in the management of acute myocardial infarction?
Key Response
rt-PA is fibrin-selective, meaning it preferentially activates plasminogen bound to fibrin in a clot, whereas streptokinase causes systemic fibrinolysis. This leads to faster recanalization of the infarct-related artery—the primary mechanism for the mortality benefit seen in GUSTO-I—but also results in a slightly higher risk of intracranial hemorrhage compared to the non-fibrin-specific streptokinase.
Given the findings of GUSTO-I, which patient factors would most influence your decision to choose an accelerated rt-PA regimen over streptokinase despite the slightly higher risk of intracranial hemorrhage?
Key Response
The absolute mortality benefit of rt-PA (1.1% absolute reduction) is most pronounced in patients with large, anterior wall MIs presenting early (within 6 hours). In contrast, for older patients (over 75) or those with significant hypertension, the higher risk of intracranial hemorrhage with rt-PA (0.72% vs 0.54% for streptokinase) necessitates a more careful risk-benefit calculation, though the overall net clinical benefit in GUSTO-I still favored rt-PA.
How did the GUSTO-I angiographic substudy refine the 'open-artery hypothesis' regarding 30-day mortality outcomes in ST-elevation myocardial infarction?
Key Response
The angiographic substudy demonstrated that accelerated rt-PA achieved TIMI grade 3 flow (complete patency) in 54% of patients at 90 minutes, compared to only 31-32% in the streptokinase groups. This established that the survival advantage of rt-PA was directly attributable to more rapid and complete restoration of coronary blood flow, confirming that early patency is a valid surrogate for improved clinical outcomes.
While primary PCI is now the gold standard, how does GUSTO-I's evidence for 'accelerated' dosing protocols inform our contemporary pharmacoinvasive strategies for STEMI patients presenting to non-PCI capable centers?
Key Response
GUSTO-I proved that the speed of reperfusion is the critical determinant of survival, leading to the 'accelerated' front-loaded tPA dosing (giving the majority of the dose in the first 30 minutes). In modern practice, this principle supports the pharmacoinvasive strategy where fibrinolysis is initiated immediately if PCI delay exceeds 120 minutes, ensuring the earliest possible 'open artery' before transfer for definitive intervention.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
GUSTO-I utilized a 'mega-trial' design with over 41,000 patients; what are the statistical implications of using such a large sample size when evaluating secondary safety endpoints like hemorrhagic stroke?
Key Response
Large sample sizes provide the power to detect small absolute differences in primary endpoints (mortality) that might be missed in smaller trials. However, they also make the study sensitive to very small increases in rare adverse events. In GUSTO-I, the 0.2% increase in stroke with rt-PA was statistically significant only because of the massive cohort, requiring the researchers to perform a 'net clinical benefit' analysis to ensure that the saved lives (10 per 1000) outweighed the extra strokes (2 per 1000).
A major criticism of GUSTO-I was the use of subcutaneous heparin in the streptokinase arms versus intravenous heparin in the rt-PA arm. How does this lack of pharmacological uniformity in co-therapy affect the internal validity of the trial's conclusions?
Key Response
The difference in heparin administration (IV vs. SQ) introduced a confounding variable. Since IV heparin provides more reliable anticoagulation than SQ, critics argued that the superiority of rt-PA might have been partially due to better adjunctive therapy preventing re-occlusion rather than the fibrinolytic agent itself. This methodological choice is a classic example of how 'asymmetric' co-interventions can complicate the interpretation of a randomized head-to-head drug trial.
How do the GUSTO-I results continue to support the Class I, Level A recommendations for fibrin-specific agents in current STEMI guidelines when primary PCI is unavailable?
Key Response
Current ACC/AHA STEMI guidelines recommend fibrin-specific agents (Alteplase, Tenecteplase, Reteplase) over non-fibrin-specific agents like Streptokinase. GUSTO-I provided the definitive Level A evidence for this preference by showing a statistically significant mortality advantage for rt-PA. While newer bolus-based agents like Tenecteplase are now preferred for ease of use, their approval was based on non-inferiority to the accelerated rt-PA regimen established as the standard of care by GUSTO-I.
Clinical Landscape
Noteworthy Related Trials
GISSI-1 Trial
Tested
Intravenous streptokinase
Population
Patients with acute myocardial infarction
Comparator
Standard conventional therapy
Endpoint
In-hospital mortality
ISIS-2 Trial
Tested
Streptokinase and/or aspirin
Population
Patients with suspected acute myocardial infarction
Comparator
Placebo
Endpoint
5-week vascular mortality
GUSTO-IIb Trial
Tested
Hirudin versus heparin
Population
Patients with acute coronary syndromes
Comparator
Heparin
Endpoint
Combined incidence of death, myocardial infarction, or reinfarction at 30 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis